To the Editor: Hereditary cancer predisposition syndromes (HCPS) account for at least 10% of paediatric cancers.1 Li‐Fraumeni syndrome (LFS) is a dominant HCPS caused by mutations in the TP53 gene and is associated with an 80–90% lifetime risk of cancer, commencing in infancy.2 Children of affected individuals are at 50% risk of inheriting the family mutation.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Scollon S, Anglin AK, Thomas M, et al. A comprehensive review of pediatric tumors and associated cancer predisposition syndromes. J Genet Couns 2017; 26: 387–434.
- 2. Amadou A, Achatz MIW, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li‐Fraumeni syndrome. Curr Opin Oncol 2018; 30: 23–29.
- 3. Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li‐Fraumeni syndrome: 11 year follow‐up of a prospective observational study. Lancet Oncol 2016; 17: 1295–1305.
- 4. eviQ. TP53 (Li‐Fraumeni) — risk management (child) [website]. Sydney: Cancer Institute NSW; 2012. https://www.eviq.org.au/cancer-genetics/adult/risk-management/1349-tp53-li-fraumeni-risk-management-child (viewed July 2020).
- 5. McGill BC, Wakefield CE, Vetsch J, et al. “I remember how I felt, but I don’t remember the gene”: families’ experiences of cancer‐related genetic testing in childhood. Pediatr Blood Cancer 2019; 66: e27762.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.